Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:BLRX NASDAQ:INKT NASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.52+11.0%$2.69$1.78▼$8.56$73.86M0.9281,099 shs172,482 shsBLRXBioLineRx$3.67+3.4%$4.09$2.30▼$26.80$15.64M1.2630,225 shs8,257 shsINKTMiNK Therapeutics$14.80+7.6%$16.08$4.56▼$76.00$66.94M0.3384,734 shs51,341 shsQNTMQuantum Biopharma$14.06-1.6%$20.64$2.70▼$38.25$53.63M0.77140,908 shs117,584 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%+14.29%+43.67%+24.38%-48.01%BLRXBioLineRx0.00%-3.17%+0.55%-36.06%-85.32%INKTMiNK Therapeutics0.00%+3.93%+16.90%+103.86%+85.19%QNTMQuantum Biopharma0.00%-16.56%-45.94%-9.00%+1,405,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.52+11.0%$2.69$1.78▼$8.56$73.86M0.9281,099 shs172,482 shsBLRXBioLineRx$3.67+3.4%$4.09$2.30▼$26.80$15.64M1.2630,225 shs8,257 shsINKTMiNK Therapeutics$14.80+7.6%$16.08$4.56▼$76.00$66.94M0.3384,734 shs51,341 shsQNTMQuantum Biopharma$14.06-1.6%$20.64$2.70▼$38.25$53.63M0.77140,908 shs117,584 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%+14.29%+43.67%+24.38%-48.01%BLRXBioLineRx0.00%-3.17%+0.55%-36.06%-85.32%INKTMiNK Therapeutics0.00%+3.93%+16.90%+103.86%+85.19%QNTMQuantum Biopharma0.00%-16.56%-45.94%-9.00%+1,405,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.75Moderate Buy$19.75461.08% UpsideBLRXBioLineRx 3.50Strong Buy$26.00608.45% UpsideINKTMiNK Therapeutics 2.60Moderate Buy$37.50153.38% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BLRX, ADVM, INKT, and QNTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.008/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $12.006/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M73.85N/AN/A$3.40 per share1.04BLRXBioLineRx$28.94M0.54N/AN/A$4.04 per share0.91INKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)BLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-45.34%-49.74%-17.54%11/24/2025 (Estimated)INKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)QNTMQuantum Biopharma-$14.20M-$14.02N/AN/AN/AN/A-270.22%-131.87%11/10/2025 (Estimated)Latest BLRX, ADVM, INKT, and QNTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BLRXBioLineRx-$0.35-$1.00-$0.65-$1.00$0.66 million$0.30 million8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/A8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/6/2025Q2 2025QNTMQuantum Biopharma-$0.17-$3.23-$3.06-$3.23$2.89 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54BLRXBioLineRx0.332.061.87INKTMiNK TherapeuticsN/A0.150.15QNTMQuantum BiopharmaN/A0.780.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%BLRXBioLineRx1.56%INKTMiNK Therapeutics2.87%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%BLRXBioLineRx1.10%INKTMiNK Therapeutics22.48%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableBLRXBioLineRx404.26 million4.22 millionOptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataQNTMQuantum BiopharmaN/A3.82 million3.49 millionN/ABLRX, ADVM, INKT, and QNTM HeadlinesRecent News About These CompaniesQuantum Biopharma (NASDAQ:QNTM) Shares Up 2.4% - Should You Buy?August 30, 2025 | marketbeat.comQuantum Group announces corporate updatesAugust 21, 2025 | msn.comQuantum BioPharma Announces Update to Previously Announced Private PlacementAugust 11, 2025 | newsfilecorp.comNWhy Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational DrugAugust 11, 2025 | msn.comQuantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis TrialAugust 11, 2025 | globenewswire.comQuantum BioPharma Reports Positive Phase 1 Results for MS Drug Lucid-MSAugust 9, 2025 | theglobeandmail.comQuantum BioPharma Pursues Legal Action Over Alleged Stock ManipulationAugust 9, 2025 | theglobeandmail.comQuantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis PatientsAugust 8, 2025 | globenewswire.comQuantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of DebtAugust 7, 2025 | globenewswire.comQuantum Biopharma (QNTM) to Release Earnings on WednesdayAugust 7, 2025 | marketbeat.comQuantum BioPharma stock falls after clinical trial report releaseAugust 5, 2025 | investing.comQuantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)August 5, 2025 | globenewswire.comQuantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/SpoofingAugust 4, 2025 | globenewswire.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPOJuly 31, 2025 | globenewswire.comQuantum BioPharma Makes Strategic Investment in GameStopJuly 24, 2025 | theglobeandmail.comQuantum BioPharma purchases 2,000 shares of GameStopJuly 22, 2025 | msn.comQuantum BioPharma stock falls after GameStop share purchaseJuly 22, 2025 | investing.comQuantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom - MorningstarJuly 9, 2025 | morningstar.comMQuantum BioPharma Ltd. (QNTM) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comQuantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United KingdomJuly 8, 2025 | finance.yahoo.comQNTM - Quantum BioPharma Ltd Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLRX, ADVM, INKT, and QNTM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$3.52 +0.35 (+11.04%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.58 +0.06 (+1.70%) As of 09/5/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.BioLineRx NASDAQ:BLRX$3.67 +0.12 (+3.38%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$3.64 -0.04 (-0.95%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.MiNK Therapeutics NASDAQ:INKT$14.80 +1.05 (+7.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.01 +0.21 (+1.45%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Quantum Biopharma NASDAQ:QNTM$14.06 -0.23 (-1.61%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.13 +0.07 (+0.50%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
